Igenomix was created when it was spun out from Instituto Valenciano de Infertilidad (IVI) in 2011. Today it is one of the world’s leading providers of advanced services in reproductive genetics, operating from eight laboratories worldwide.
Its constant efforts in R&D enable Igenomix to create and develop specific tools to support professionals in the field of reproductive medicine. Specialist services offered include PGS (Pre-Implantation Genetic Screening), NACE (Non-invasive Prenatal Test); CGT (Carrier Genetic Test); PGD (Preimplantation Genetic Diagnosis) and ERA (Endometrial Receptivity Array).
In the media
1st April 2019
Evolving investments in gene technology
21st October 2019
- Cheers. - cheers.- The age of the father, unlike the mother, does not result in an increase in chromosomal abnormal embryos
of the father, unlike the mother, does not produce an increase in chromosomally abnormal embryos, as revealed by a study carried out by Igenomix and published in the 'Journal of Assisted
20th October 2019
Low birth rate but they win: the unstoppable 'boom' of the fertility industry
increasing it by 5% or 10% more is very difficult", explains David Jiménez, CEO of Igenomix, a Valencian company of reproductive genetics founded